Home Cart Sign in  
Chemical Structure| 74150-27-9 Chemical Structure| 74150-27-9

Structure of Pimobendan
CAS No.: 74150-27-9

Chemical Structure| 74150-27-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pimobendan is a selective inhibitor of PDE3 with IC50 of 0.32 μM.

Synonyms: UD-CG115; UD-CG 115 BS

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pimobendan

CAS No. :74150-27-9
Formula : C19H18N4O2
M.W : 334.37
SMILES Code : O=C1CC(C)C(C2=CC=C3C(N=C(C4=CC=C(OC)C=C4)N3)=C2)=NN1
Synonyms :
UD-CG115; UD-CG 115 BS
MDL No. :MFCD00761648
InChI Key :GLBJJMFZWDBELO-UHFFFAOYSA-N
Pubchem ID :4823

Safety of Pimobendan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PDE3

    PDE3, IC50:0.32 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Cardiomyocytes 3 μM and 10 μM 10 minutes To investigate the effects of Pimobendan on cardiomyocyte contraction and calcium transients. Results showed that Pimobendan enhanced contractility through Ca2+ sensitization and PDE3 inhibition, but may induce triggered activity in end-stage HF models. PMC4403100
HepG2.2.15 cells 20 μM 3 days Screening for potential HBsAg inhibitors, Pimobendan significantly inhibited HBsAg secretion PMC9204083
HepG2-NTCP cells 15 μM or 30 μM 6 days Validating the anti-HBV activity of Pimobendan, Pimobendan significantly reduced HBsAg and HBV core DNA levels PMC9204083
Primary human hepatocytes (PHH) 0 to 300 μM 72 hours Assessing the cytotoxicity of Pimobendan, Pimobendan showed low cytotoxicity in PHH PMC9204083

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
HBV transgenic mice HBV transgenic mouse model Oral gavage 10 mg/kg or 30 mg/kg Once daily, continuous treatment Evaluating the anti-HBV activity of Pimobendan in vivo, Pimobendan significantly reduced serum HBsAg and intrahepatic HBV RNA levels PMC9204083
Mice Genetic dilated cardiomyopathy mouse model Oral 10 mg/kg/day and 100 mg/kg/day Once daily To evaluate the therapeutic effects of Pimobendan in different stages of HF in mice. Results showed that Pimobendan significantly extended lifespan and prevented myocardial remodeling in compensated HF, but dose-dependently increased the risk of sudden death in end-stage HF. PMC4403100

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.99mL

0.60mL

0.30mL

14.95mL

2.99mL

1.50mL

29.91mL

5.98mL

2.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories